Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease
International Journal of Radiation Oncology, Biology, Physics, Volume 11, No. 8, Year 1985
Notification
URL copied to clipboard!
Description
Sixty-three evaluable patients with limited small cell lung carcinoma were entered into two pilot studies alternating 6 cycles of combination chemotherapy (Doxorubicin 40 mg/m2 d 1; VP16213 75 mg/m2 d 1, 2, 3; Cyclophosphamide 300 mg/m2 d 3, 4, 5, 6; and Methotrexate 400 mg/m2 d 2-plus folinic acid rescue-or Cis-Platinum 100 mg/m2 d 2) with 3 courses of mediastinal radiotherapy as induction treatment. The first course of radiotherapy started 10 days after the second cycle of chemotherapy; there was a 7 day rest between chemotherapy and radiotherapy courses. This 6 month induction treatment was followed by a maintenance chemotherapy. The total mediastinal radiation dose was increased from 4500 rad in the first study to 5500 rad in the second. Both protocols obtained a complete response (CR) rate of greater than 85% (with fiberoptic bronchoscopy and histological verification). Local control at 2 years was 61% in the first study and 82% in the second. Relapse-free survival at 2 years was 32 and 37%, respectively. Toxicity was acceptable. We conclude that our results justify further clinical research in alternating radiotherapy and chemotherapy schedules. © 1985.
Authors & Co-Authors
Arrìagada, Roderigo
France
Committee of Thoracic Diseases
Le-Chevalier, Thierry
France
Committee of Thoracic Diseases
Baldeyrou, Pierre
France
Committee of Thoracic Diseases
Pico, JoséL Luis
France, Villejuif
Institut de Cancerologie Gustave Roussy
Ruffié, Pierre A.
France, Villejuif
Institut de Cancerologie Gustave Roussy
Martin, Michael D.
France, Creteil
Centre Hospitalier Intercommunal Creteil
El Bakry, H.
Egypt, Giza
National Cancer Institute
Duroux, P.
France, Clamart
Hopital Antoine Beclere
Bignon, J.
France, Creteil
Centre Hospitalier Intercommunal Creteil
Lenfant, B.
Unknown Affiliation
Hayat, Marcel
France, Villejuif
Institut de Cancerologie Gustave Roussy
Rouesse, J. G.
France, Villejuif
Institut de Cancerologie Gustave Roussy
Sancho-Garnier, Hélène
Unknown Affiliation
Tubiana, M.
France, Villejuif
Institut de Cancerologie Gustave Roussy
Statistics
Citations: 97
Authors: 14
Affiliations: 5
Identifiers
Doi:
10.1016/0360-3016(85)90333-5
ISSN:
03603016
Research Areas
Cancer